Therapeutic options here are based on EMA drug approvals with deviating approval details clearly marked. Drugs availability may vary in your country.

Abbreviations

AC – Adenocarcinoma
ALK – Anaplastic lymphoma kinase
BRAF – Protein kinase B-rapidly accelerated fibrosarcoma
CE-IVD – CE-marked in vitro diagnostic device​​​​​​​
EGF – Epidermal growth factor
EGFR – Epidermal growth factor receptor
EMA – European Medicines Agency
FFPE – Formalin-fixed paraffin-embedded (tissue)
FGFR1 – Fibroblast growth factor receptor 1
FISH – Fluorescence in situ hybridization​​​​​​​
HER2 – Human epidermal receptor 2
HGF – Hepatocyte growth factor
IHC – Immunohistochemistry
IVD – In vitro diagnostic device
KRAS – Kirsten rat sarcoma viral oncogene
LCC – Large cell carcinoma
LDT – Lab developed test
MAP kinase – Mitogen-activated protein kinase
MET – MET proto-oncogene
NGS – Next generation sequencing
NSCLC – Non small cell lung cancer
NTRK – Neurotrophic receptor tyrosine kinase
PCR – Polymerase chain reaction
PD-L1 – Programmed cell death ligand 1
QuIP – Qualitätssicherungs-Initiative Pathologie GmbH
RET – Rat sarcoma
ROS1 – Proto oncogene 1
SCC – Squamous cell carcinoma
SCLC – Small cell lung cancer
SOP – Standard operating procedure
TKI – Tyrosine kinase inhibitor